Opus Genetics (IRD) Competitors $1.18 +0.08 (+7.27%) Closing price 08/14/2025 04:00 PM EasternExtended Trading$1.16 -0.02 (-2.12%) As of 04:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock IRD vs. MREO, TLSA, SCPH, IMMP, TKNO, ALMS, FENC, NMRA, GALT, and PBYIShould you be buying Opus Genetics stock or one of its competitors? The main competitors of Opus Genetics include Mereo BioPharma Group (MREO), Tiziana Life Sciences (TLSA), scPharmaceuticals (SCPH), Prima BioMed (IMMP), Alpha Teknova (TKNO), Alumis (ALMS), Adherex Technologies (FENC), Neumora Therapeutics (NMRA), Galectin Therapeutics (GALT), and Puma Biotechnology (PBYI). These companies are all part of the "pharmaceutical products" industry. Opus Genetics vs. Its Competitors Mereo BioPharma Group Tiziana Life Sciences scPharmaceuticals Prima BioMed Alpha Teknova Alumis Adherex Technologies Neumora Therapeutics Galectin Therapeutics Puma Biotechnology Mereo BioPharma Group (NASDAQ:MREO) and Opus Genetics (NASDAQ:IRD) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends. Which has higher earnings & valuation, MREO or IRD? Mereo BioPharma Group has higher earnings, but lower revenue than Opus Genetics. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMereo BioPharma Group$10M27.19-$43.25M-$0.07-24.43Opus Genetics$10.99M6.41-$57.53M-$2.10-0.56 Is MREO or IRD more profitable? Mereo BioPharma Group has a net margin of 0.00% compared to Opus Genetics' net margin of -377.89%. Mereo BioPharma Group's return on equity of -80.00% beat Opus Genetics' return on equity.Company Net Margins Return on Equity Return on Assets Mereo BioPharma GroupN/A -80.00% -66.94% Opus Genetics -377.89%-397.51%-146.10% Which has more volatility & risk, MREO or IRD? Mereo BioPharma Group has a beta of 0.47, meaning that its stock price is 53% less volatile than the S&P 500. Comparatively, Opus Genetics has a beta of 0.01, meaning that its stock price is 99% less volatile than the S&P 500. Do insiders and institutionals hold more shares of MREO or IRD? 62.8% of Mereo BioPharma Group shares are held by institutional investors. Comparatively, 15.0% of Opus Genetics shares are held by institutional investors. 5.5% of Mereo BioPharma Group shares are held by insiders. Comparatively, 6.6% of Opus Genetics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the media favor MREO or IRD? In the previous week, Mereo BioPharma Group had 8 more articles in the media than Opus Genetics. MarketBeat recorded 15 mentions for Mereo BioPharma Group and 7 mentions for Opus Genetics. Mereo BioPharma Group's average media sentiment score of 0.34 beat Opus Genetics' score of 0.33 indicating that Mereo BioPharma Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mereo BioPharma Group 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Opus Genetics 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate MREO or IRD? Mereo BioPharma Group presently has a consensus target price of $7.20, suggesting a potential upside of 321.05%. Opus Genetics has a consensus target price of $7.33, suggesting a potential upside of 521.47%. Given Opus Genetics' higher possible upside, analysts clearly believe Opus Genetics is more favorable than Mereo BioPharma Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mereo BioPharma Group 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Opus Genetics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryMereo BioPharma Group beats Opus Genetics on 13 of the 17 factors compared between the two stocks. Get Opus Genetics News Delivered to You Automatically Sign up to receive the latest news and ratings for IRD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IRD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IRD vs. The Competition Export to ExcelMetricOpus GeneticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$65.63M$3.10B$5.61B$9.84BDividend YieldN/A2.23%4.61%4.07%P/E Ratio-0.6120.4930.2825.74Price / Sales6.41356.37460.47115.79Price / CashN/A43.0338.2159.48Price / Book5.628.608.856.15Net Income-$57.53M-$54.65M$3.25B$265.06M7 Day Performance10.28%5.86%3.72%2.60%1 Month Performance7.27%8.86%5.86%2.83%1 Year PerformanceN/A13.33%30.34%25.58% Opus Genetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IRDOpus Genetics1.863 of 5 stars$1.18+7.3%$7.33+521.5%N/A$65.63M$10.99M-0.6114News CoverageEarnings ReportGap DownHigh Trading VolumeMREOMereo BioPharma Group2.0481 of 5 stars$1.65+8.2%$7.20+337.7%-56.7%$259.97M$10M-23.3640News CoverageEarnings ReportAnalyst RevisionGap DownTLSATiziana Life Sciences0.6291 of 5 stars$2.22-9.8%N/A+83.5%$259.41MN/A0.008News CoverageGap UpSCPHscPharmaceuticals4.4737 of 5 stars$4.81+3.1%$14.00+191.4%+3.3%$255.84M$36.33M-2.6530News CoverageShort Interest ↓IMMPPrima BioMed1.4686 of 5 stars$1.74+2.1%$7.00+303.5%-20.4%$254.68M$5.14M0.002,021TKNOAlpha Teknova2.4567 of 5 stars$4.73+7.1%$10.00+111.6%+29.4%$253.57M$37.74M-11.30240Gap DownALMSAlumis2.884 of 5 stars$4.55+4.7%$19.80+335.6%-65.5%$247.29MN/A0.00N/ANews CoverageEarnings ReportAnalyst ForecastGap DownFENCAdherex Technologies2.1377 of 5 stars$8.87+7.5%$13.00+46.6%+60.0%$245.28M$47.54M-17.2910News CoverageGap DownNMRANeumora Therapeutics2.9123 of 5 stars$1.50+3.8%$7.14+377.8%-85.9%$242.12MN/A-0.95108GALTGalectin Therapeutics2.2505 of 5 stars$3.78-2.7%$6.00+58.9%+80.8%$240.50MN/A-5.289News CoverageEarnings ReportAnalyst ForecastPBYIPuma Biotechnology4.1455 of 5 stars$4.80-1.0%$7.00+45.7%+95.9%$240.42M$230.50M4.87200Gap DownHigh Trading Volume Related Companies and Tools Related Companies Mereo BioPharma Group Alternatives Tiziana Life Sciences Alternatives scPharmaceuticals Alternatives Prima BioMed Alternatives Alpha Teknova Alternatives Alumis Alternatives Adherex Technologies Alternatives Neumora Therapeutics Alternatives Galectin Therapeutics Alternatives Puma Biotechnology Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IRD) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opus Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Opus Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access